Objective To comprehensively analyze the clinical effects of oxiracetam combined with Xingnaojing in the treatment of traumatic brain injury, and its effects on neuronal injury.
Methods Seventy-six patients with traumatic brain injury were randomly divided into the observation group and control group(38 cases in each group). On the basis of comprehensive treatment, the control group was treated with oxiracetam, and the observation group was treated with oxiracetam combined with Xingnaojing. The Glasgow coma score(GCS), acute physiological and chronic health status scores(APACHE Ⅱ), degree of neuron injuryserum levels of glial fibrillary acidic protein(GFAP), neuron specific enolase(NSE), calcium binding protein S100B and myelin basic protein(MBP), nerve injury repair indexeslevels of heat shock protein(HSP)-90, HSP-70, HSP-27 and nerve growth factor(NGF), inflammatory chemokinesserum monocyte chemokine 1(MCP-1), aspartate cysteine-specific proteinase-3(Caspase-3) and factors regulating the expression and secretion of activated normal T cells(RANTES) in two groups were compared between before treatment and after 14 and 28 days of treatment. The prognosis and adverse reactions between two groups were compared.
Results Compared with before treatment, the GCS scores in two groups increased, the APACHE Ⅱ scores decreased in two groups after 14 and 28 days of treatment, and which in observation group was better than that in control group(P < 0.01). The results of evaluation after 28 days of treatment showed that there was no statistical significance in the rate of good prognosis between two groups(P>0.05). After 14 and 28 days of treatment, the serum levels of GFAP, NSE, S100B, MBP, HSP-90, HSP-70, HSP-27 and NGF in two groups decreased compared with before treatment, and the decrease amplitude in observation groups was higher than that in control group(P < 0.05 to P < 0.01). The serum levels of MCP-1, Caspase-3 and RANTES in two groups after 14 and 28 days of treatment were lower than that before treatment, and which in observation group was lower than that in control group(P < 0.05 to P < 0.01). There was no statistical significance in the incidence rate of adverse reactions between two groups(P>0.05).
Conclusions Oxiracetam combined with Xingnaojing has significant clinical effect in the treatment of traumatic brain injury, which can effectively relieve the nerve injury, reduce the serum content of MCP-1, Caspase-3 and RANTES, and alleviate local inflammation. The recovery and prognosis of patients are good.
DownLoad: